- Home
- TENB vs AKRO Comparison
TENB vs AKRO Comparison
Compare TENB & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TENB | AKRO |
|---|---|---|
| Founded | 2002 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 4.5B |
| IPO Year | 2018 | 2019 |
Fundamental Metrics
Financial Performance| Metric | TENB | AKRO |
|---|---|---|
| Price | $26.24 | $54.54 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 17 | 10 |
| Target Price | $39.25 | ★ $73.56 |
| AVG Volume (30 Days) | 1.1M | ★ 1.7M |
| Earning Date | 10-29-2025 | 11-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $974,603,000.00 | N/A |
| Revenue This Year | $12.22 | N/A |
| Revenue Next Year | $7.62 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 11.05 | N/A |
| 52 Week Low | $25.28 | $21.34 |
| 52 Week High | $45.45 | $58.40 |
Technical Indicators
Market Signals| Indicator | TENB | AKRO |
|---|---|---|
| Relative Strength Index (RSI) | 40.17 | 66.54 |
| Support Level | $26.24 | $54.22 |
| Resistance Level | $27.07 | $54.70 |
| Average True Range (ATR) | 0.65 | 0.14 |
| MACD | 0.13 | -0.11 |
| Stochastic Oscillator | 46.91 | 64.18 |
Price Performance
Historical ComparisonAbout TENB Tenable Holdings Inc.
Founded in 2002, Tenable is a cybersecurity company that began providing vulnerability management solutions under its Nessus software. In recent years, Tenable has expanded its portfolio to provide a broader range of exposure management modules. Solutions include cloud security and compliance, active directory management, operational technology security and advanced vulnerability analytics. The Maryland-based company went public in 2018.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.